(EVO) Evotec SE - Ratings and Ratios

Evotec SE ADR (NASDAQ:EVO), a global leader in drug discovery and development, partners with pharmaceutical and biotechnology firms to advance therapeutic solutions. Their expertise spans multiple therapeutic areas, including autoimmune diseases, cancer, CNS disorders, diabetes, fibrosis, immunology, infectious diseases, kidney and liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and womens health. Evotec employs cutting-edge technologies and integrated platforms to accelerate drug development processes.

Evotec has established strategic collaborations with prominent entities such as SK bioscience, JingXin, and Pfizer, focusing on innovative targets and biomarkers. Their partnership with Dewpoint Therapeutics targets biomolecular condensates, a novel therapeutic domain. Collaborations with academic institutions like Inserm and CHDI Foundation underscore their commitment to advancing metabolic and neurodegenerative disease research.

Originally incorporated in 1993 as Evotec AG, the company rebranded as Evotec SE in 2019, reflecting its European stock designation. Headquartered in Hamburg, Germany, Evotec is listed on NASDAQ under the ticker EVO, classified under the Biotechnology industry with a market capitalization of $1.294 billion.

3-Month Forecast

Technically, EVOs stock shows potential upside with the last price ($4.29) above its SMA 20 ($3.67) and SMA 50 ($3.69), signaling a bullish trend. However, approaching the SMA 200 ($3.98) may present resistance. Low ATR (0.17) suggests continued volatility management.

Fundamentally, a forward P/E of 59.88 reflects high growth expectations, though the negative RoE (-17.69%) raises profitability concerns. The moderate P/S ratio (1.62) and P/B ratio (1.17) indicate a valuation aligned with industry peers. The stock may experience short-term upside driven by partnership potential, yet investors should monitor profitability metrics and valuation multiples.